Display options
Cite
Roma-Rodrigues C, Rivas-García L, Baptista PV, et al. Gene Therapy in Cancer Treatment: Why Go Nano?. Pharmaceutics. 2020;12(3)doi: 10.3390/pharmaceutics12030233.
Roma-Rodrigues, C., Rivas-García, L., Baptista, P. V., & Fernandes, A. R. (2020). Gene Therapy in Cancer Treatment: Why Go Nano?. Pharmaceutics, 12(3), . https://doi.org/10.3390/pharmaceutics12030233
Roma-Rodrigues, Catarina, et al. "Gene Therapy in Cancer Treatment: Why Go Nano?." Pharmaceutics vol. 12,3 (2020). doi: https://doi.org/10.3390/pharmaceutics12030233
Roma-Rodrigues C, Rivas-García L, Baptista PV, Fernandes AR. Gene Therapy in Cancer Treatment: Why Go Nano?. Pharmaceutics. 2020 Mar 05;12(3). doi: 10.3390/pharmaceutics12030233. PMID: 32151052; PMCID: PMC7150812.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2020 Mar 05;12(3). doi: 10.3390/pharmaceutics12030233.

Gene Therapy in Cancer Treatment: Why Go Nano?.

Pharmaceutics

Catarina Roma-Rodrigues, Lorenzo Rivas-García, Pedro V Baptista, Alexandra R Fernandes

Affiliations

  1. UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Campus de Caparica, 2829-516 Caparica, Portugal.
  2. Biomedical Research Centre, Institute of Nutrition and Food Technology, Department of Physiology, Faculty of Pharmacy, University of Granada, Avda. del Conocimiento s/n. 18071 Armilla, Granada, Spain.

PMID: 32151052 PMCID: PMC7150812 DOI: 10.3390/pharmaceutics12030233

Abstract

The proposal of gene therapy to tackle cancer development has been instrumental for the development of novel approaches and strategies to fight this disease, but the efficacy of the proposed strategies has still fallen short of delivering the full potential of gene therapy in the clinic. Despite the plethora of gene modulation approaches, e.g., gene silencing, antisense therapy, RNA interference, gene and genome editing, finding a way to efficiently deliver these effectors to the desired cell and tissue has been a challenge. Nanomedicine has put forward several innovative platforms to overcome this obstacle. Most of these platforms rely on the application of nanoscale structures, with particular focus on nanoparticles. Herein, we review the current trends on the use of nanoparticles designed for cancer gene therapy, including inorganic, organic, or biological (e.g., exosomes) variants, in clinical development and their progress towards clinical applications.

Keywords: gene delivery; gene therapy; nanomedicine; nanoparticles; tumor microenvironment

Conflict of interest statement

vascular endothelial growth factor

References

  1. Materials (Basel). 2020 Jan 13;13(2): - PubMed
  2. Ther Deliv. 2018 Mar 1;9(4):269-285 - PubMed
  3. J Drug Target. 2017 Jul;25(6):513-522 - PubMed
  4. Expert Opin Biol Ther. 2018 Sep;18(9):959-972 - PubMed
  5. Stem Cell Rev Rep. 2020 Feb;16(1):103-117 - PubMed
  6. Hepatology. 2007 Mar;45(3):746-54 - PubMed
  7. Cell Death Dis. 2018 Feb 7;9(2):177 - PubMed
  8. Sci Rep. 2019 Feb 14;9(1):2069 - PubMed
  9. Materials (Basel). 2018 Feb 23;11(2): - PubMed
  10. Mol Cell Ther. 2014 Sep 10;2:27 - PubMed
  11. Int J Mol Sci. 2019 Sep 21;20(19): - PubMed
  12. Methods Mol Biol. 2017;1530:319-336 - PubMed
  13. Medicine (Baltimore). 2019 May;98(18):e15311 - PubMed
  14. Bioconjug Chem. 2018 Apr 18;29(4):1302-1311 - PubMed
  15. Mol Ther Methods Clin Dev. 2016 Apr 06;3:16023 - PubMed
  16. Biomed Res Int. 2014;2014:619829 - PubMed
  17. Photochem Photobiol. 2018 Jul;94(4):765-774 - PubMed
  18. Cancer Res. 1986 Oct;46(10):5276-81 - PubMed
  19. Curr Top Med Chem. 2019;19(23):2143-2157 - PubMed
  20. Expert Opin Drug Discov. 2017 Feb;12(2):141-157 - PubMed
  21. Pharm Res. 2019 Jul 9;36(9):133 - PubMed
  22. Oncol Lett. 2019 May;17(5):4487-4493 - PubMed
  23. Biomaterials. 2018 Jul;171:207-218 - PubMed
  24. Nat Methods. 2018 Mar;15(3):183-186 - PubMed
  25. Cancers (Basel). 2019 Dec 12;11(12): - PubMed
  26. Transfus Med Hemother. 2019 Feb;46(1):15-24 - PubMed
  27. Polymers (Basel). 2019 Sep 18;11(9): - PubMed
  28. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  29. Int J Nanomedicine. 2018 Jul 04;13:3921-3935 - PubMed
  30. Curr Pharm Des. 2018;24(23):2664-2672 - PubMed
  31. Exp Mol Med. 2019 Nov 5;51(11):1-11 - PubMed
  32. Int J Mol Sci. 2013 Jan 14;14(1):1629-54 - PubMed
  33. Lab Chip. 2020 Feb 7;20(3):548-557 - PubMed
  34. J Exp Med. 2013 Jun 3;210(6):1137-51 - PubMed
  35. Front Immunol. 2019 Apr 30;10:957 - PubMed
  36. J Gene Med. 2019 Jul;21(7):e3107 - PubMed
  37. Methods Mol Biol. 2019;1943:141-152 - PubMed
  38. Cancer Immunol Immunother. 2018 May;67(5):785-795 - PubMed
  39. Mol Pharm. 2020 Jan 6;17(1):229-238 - PubMed
  40. J Cell Physiol. 2019 Feb 5;: - PubMed
  41. Nat Rev Cancer. 2017 Aug;17(8):457-474 - PubMed
  42. Anticancer Res. 2019 Apr;39(4):1785-1793 - PubMed
  43. Front Bioeng Biotechnol. 2017 Dec 18;5:79 - PubMed
  44. Cancer Immunol Immunother. 2019 Oct;68(10):1701-1712 - PubMed
  45. Cancers (Basel). 2019 May 03;11(5): - PubMed
  46. Nanoscale Res Lett. 2014 May 21;9(1):252 - PubMed
  47. Nanomaterials (Basel). 2017 Apr 28;7(5): - PubMed
  48. Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):274-283 - PubMed
  49. Expert Opin Biol Ther. 2016;16(4):443-61 - PubMed
  50. Biomacromolecules. 2020 Mar 9;21(3):1136-1148 - PubMed
  51. Nat Rev Drug Discov. 2017 Mar;16(3):203-222 - PubMed
  52. ACS Nano. 2012 Sep 25;6(9):8316-24 - PubMed
  53. Biomater Sci. 2020 Mar 17;8(6):1490-1501 - PubMed
  54. Expert Rev Mol Diagn. 2018 Sep;18(9):767-773 - PubMed
  55. J Environ Pathol Toxicol Oncol. 2018;37(3):209-230 - PubMed
  56. Cancer Immunol Res. 2014 Feb;2(2):154-66 - PubMed
  57. Toxicol Ind Health. 2018 Mar;34(3):200-210 - PubMed
  58. Chromosoma. 2018 Dec;127(4):405-420 - PubMed
  59. Nanomaterials (Basel). 2017 Jan 11;7(1): - PubMed
  60. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9 - PubMed
  61. Science. 2020 Jan 10;367(6474):131 - PubMed
  62. Nat Biomed Eng. 2018 Nov;2(11):797-809 - PubMed
  63. Pharmaceutics. 2019 Jul 24;11(8): - PubMed
  64. Int J Biol Macromol. 2020 Mar 15;147:799-808 - PubMed
  65. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S383-S388 - PubMed
  66. Mol Cancer. 2019 Apr 2;18(1):75 - PubMed
  67. Pharmaceutics. 2019 Nov 17;11(11): - PubMed
  68. J Mater Chem B. 2019 Feb 14;7(6):876-896 - PubMed
  69. Cell Mol Life Sci. 2019 Nov 6;: - PubMed
  70. Arch Toxicol. 2017 Sep;91(9):2967-3010 - PubMed
  71. Cancers (Basel). 2019 May 08;11(5): - PubMed
  72. Cancers (Basel). 2019 Nov 25;11(12): - PubMed
  73. J Cancer. 2017 Feb 25;8(5):761-773 - PubMed
  74. Antimicrob Resist Infect Control. 2019 Apr 3;8:62 - PubMed
  75. Front Bioeng Biotechnol. 2019 Aug 14;7:197 - PubMed
  76. Adv Drug Deliv Rev. 2019 Apr;144:90-111 - PubMed
  77. Pharm Res. 2016 Jun;33(6):1351-8 - PubMed
  78. Mol Ther Methods Clin Dev. 2016 Dec 31;4:92-101 - PubMed
  79. PLoS One. 2018 Jan 23;13(1):e0191607 - PubMed
  80. Polymers (Basel). 2019 Apr 25;11(4): - PubMed
  81. Mol Pharm. 2019 May 6;16(5):2129-2141 - PubMed
  82. Biomacromolecules. 2018 Aug 13;19(8):3586-3593 - PubMed
  83. Front Cell Dev Biol. 2019 Apr 24;7:60 - PubMed
  84. Int J Mol Sci. 2017 May 24;18(6): - PubMed
  85. Gene. 2019 Jun 15;701:32-40 - PubMed
  86. Mater Sci Eng C Mater Biol Appl. 2019 Oct;103:109828 - PubMed
  87. Biomed Res Int. 2014;2014:179486 - PubMed
  88. Int J Nanomedicine. 2008;3(2):169-80 - PubMed
  89. Nat Cell Biol. 2019 Dec;21(12):1468-1478 - PubMed
  90. Discov Med. 2019 Jan;27(146):45-55 - PubMed
  91. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4139-43 - PubMed
  92. Oncologist. 2019 Jun;24(6):747-e218 - PubMed
  93. J Genet Syndr Gene Ther. 2013 Aug 9;4: - PubMed
  94. Int J Biol Macromol. 2018 Sep;116:880-892 - PubMed
  95. Pharmaceutics. 2019 Aug 02;11(8): - PubMed
  96. Mol Cancer. 2019 Mar 30;18(1):70 - PubMed
  97. Cancer Res. 2015 Jul 15;75(14):2800-2810 - PubMed
  98. Jpn J Clin Oncol. 2008 Dec;38(12):849-56 - PubMed
  99. Immunotherapy. 2016 Feb;8(2):179-98 - PubMed
  100. Nanomedicine (Lond). 2019 Apr;14(7):797-801 - PubMed
  101. J Control Release. 2020 Mar 10;319:63-76 - PubMed
  102. Biochem Biophys Res Commun. 2011 Dec 9;416(1-2):178-83 - PubMed
  103. Comb Chem High Throughput Screen. 2011 Dec;14(10):908-24 - PubMed
  104. Bioconjug Chem. 2019 May 15;30(5):1459-1465 - PubMed
  105. Gene Ther. 2004 Mar;11(6):497-503 - PubMed
  106. Adv Pharm Bull. 2017 Apr;7(1):3-9 - PubMed
  107. J Clin Oncol. 2014 Dec 20;32(36):4141-8 - PubMed
  108. Toxicol Rep. 2016 Jan 19;3:230-243 - PubMed
  109. J Control Release. 2019 Oct;311-312:43-49 - PubMed
  110. J Control Release. 2020 Feb;318:1-15 - PubMed
  111. Nanoscale Res Lett. 2019 Jul 30;14(1):258 - PubMed
  112. Front Chem. 2014 Jul 15;2:48 - PubMed
  113. Adv Exp Med Biol. 2020 Jan 09;: - PubMed
  114. Bioconjug Chem. 2016 Oct 19;27(10):2225-2238 - PubMed
  115. Int J Mol Sci. 2019 Nov 05;20(21): - PubMed
  116. Theranostics. 2017 Feb 27;7(5):1133-1148 - PubMed
  117. Biomaterials. 2018 Jun;167:80-90 - PubMed
  118. Trends Mol Med. 2019 Dec;25(12):1066-1079 - PubMed
  119. Front Immunol. 2018 Jan 29;9:40 - PubMed
  120. Curr Drug Metab. 2019;20(6):446-456 - PubMed
  121. J Control Release. 2019 May 10;301:76-109 - PubMed
  122. Pharmaceutics. 2019 Oct 24;11(11): - PubMed
  123. Nanoscale Res Lett. 2016 Dec;11(1):247 - PubMed
  124. Prostate. 2020 Jan;80(1):65-73 - PubMed
  125. J Funct Biomater. 2015 Jun 08;6(2):379-94 - PubMed
  126. Nano Lett. 2009 May;9(5):2059-64 - PubMed
  127. Int J Biol Macromol. 2020 Mar 1;146:773-780 - PubMed
  128. Cancer Gene Ther. 2019 Nov 2;: - PubMed
  129. Front Oncol. 2019 Oct 22;9:1076 - PubMed
  130. J Control Release. 2020 Apr 10;320:45-62 - PubMed
  131. J Hematol Oncol. 2019 Aug 28;12(1):86 - PubMed
  132. Oncotarget. 2019 Jul 30;10(46):4761-4775 - PubMed
  133. Eur J Pharm Biopharm. 2016 Dec;109:184-193 - PubMed
  134. Oncotarget. 2015 Oct 20;6(32):32774-89 - PubMed
  135. Acta Pharmacol Sin. 2019 Dec 2;: - PubMed
  136. Nat Cell Biol. 2007 Jun;9(6):654-9 - PubMed
  137. Nanomedicine. 2016 Apr;12(3):655-664 - PubMed
  138. Mater Sci Eng C Mater Biol Appl. 2020 Feb;107:110273 - PubMed
  139. Oncol Lett. 2018 Mar;15(3):2735-2742 - PubMed
  140. Molecules. 2018 Jun 11;23(6): - PubMed
  141. Gene Ther. 2020 Feb;27(1-2):85-95 - PubMed
  142. J Control Release. 2014 Sep 28;190:451-64 - PubMed
  143. Recent Results Cancer Res. 2020;214:93-128 - PubMed
  144. Recent Results Cancer Res. 2020;214:153-167 - PubMed
  145. Curr Drug Targets. 2018;19(15):1801-1817 - PubMed
  146. Autophagy. 2018;14(8):1323-1334 - PubMed
  147. Pharmaceutics. 2018 Oct 18;10(4): - PubMed
  148. Genes (Basel). 2017 Mar 02;8(3): - PubMed
  149. Int J Nanomedicine. 2019 Jul 15;14:5287-5301 - PubMed
  150. Cells. 2019 Nov 21;8(12): - PubMed
  151. Cancers (Basel). 2019 Oct 16;11(10): - PubMed
  152. Nat Rev Drug Discov. 2019 Jun;18(6):421-446 - PubMed
  153. Nanomaterials (Basel). 2019 Apr 19;9(4): - PubMed
  154. Pharmaceutics. 2018 Oct 18;10(4): - PubMed
  155. Nanomedicine (Lond). 2012 Jan;7(1):65-78 - PubMed
  156. Genes (Basel). 2019 Apr 09;10(4): - PubMed
  157. Adv Drug Deliv Rev. 2013 Dec;65(15):2023-33 - PubMed
  158. Nat Mater. 2013 Nov;12(11):958-62 - PubMed
  159. Semin Immunol. 2020 Feb;47:101387 - PubMed
  160. J Biomed Nanotechnol. 2018 Dec 1;14(12):2018-2030 - PubMed
  161. Biomater Sci. 2018 Nov 20;6(12):3251-3261 - PubMed
  162. J Control Release. 2020 Mar 10;319:407-415 - PubMed
  163. Semin Cancer Biol. 2019 Nov 5;: - PubMed
  164. Oncogene. 2019 Aug;38(33):6095-6108 - PubMed
  165. Recent Pat Nanotechnol. 2019;13(1):17-27 - PubMed
  166. J Hematol Oncol. 2015 Oct 29;8:122 - PubMed
  167. Mater Sci Eng C Mater Biol Appl. 2019 May;98:1252-1276 - PubMed
  168. Eur J Med Chem. 2017 Dec 15;142:416-423 - PubMed
  169. Stem Cell Rev Rep. 2020 Jan 3;: - PubMed
  170. Front Pharmacol. 2018 Aug 21;9:971 - PubMed
  171. Mol Ther Nucleic Acids. 2017 Jun 16;7:408-416 - PubMed
  172. Oncoimmunology. 2018 May 7;7(7):e1404216 - PubMed
  173. J Biomed Nanotechnol. 2019 Feb 1;15(2):215-416 - PubMed
  174. Int J Pharm. 2017 Aug 7;528(1-2):675-691 - PubMed
  175. Biomed Res Int. 2013;2013:782041 - PubMed
  176. Int J Nanomedicine. 2019 Jun 11;14:4353-4366 - PubMed
  177. Nat Protoc. 2013 Dec;8(12):2392-403 - PubMed
  178. Pharm Res. 2017 Sep;34(9):1886-1896 - PubMed
  179. Acta Biomater. 2017 Feb;49:36-44 - PubMed
  180. ACS Appl Mater Interfaces. 2020 Jan 29;12(4):4308-4322 - PubMed
  181. Artif Cells Nanomed Biotechnol. 2016;44(1):410-22 - PubMed
  182. Hum Mol Genet. 2012 Oct 15;21(R1):R125-34 - PubMed
  183. Mol Ther. 2016 Mar;24(3):430-46 - PubMed
  184. Int J Pharm. 2019 Jun 10;564:145-152 - PubMed
  185. Transl Cancer Res. 2017 Aug;6(Suppl 6):S1040-S1042 - PubMed
  186. Gene Ther. 2017 Aug;24(8):441-452 - PubMed
  187. Biochem Pharmacol. 2017 Nov 15;144:29-34 - PubMed
  188. Int J Nanomedicine. 2008;3(3):311-21 - PubMed
  189. J Control Release. 2015 Sep 28;214:121-33 - PubMed
  190. Nanomedicine. 2017 May;13(4):1389-1398 - PubMed
  191. Int J Clin Exp Pathol. 2019 Jan 01;12(1):205-211 - PubMed
  192. Int J Mol Sci. 2019 Nov 04;20(21): - PubMed
  193. Mol Med Rep. 2015 Aug;12(2):1783-8 - PubMed
  194. Molecules. 2018 Nov 07;23(11): - PubMed
  195. Hum Gene Ther. 2018 Feb;29(2):160-179 - PubMed
  196. Life Sci. 2020 Jan 1;240:117077 - PubMed
  197. Diseases. 2018 May 21;6(2): - PubMed
  198. J Drug Target. 2016;24(5):457-67 - PubMed
  199. Eur J Pharm Sci. 2018 Oct 15;123:173-183 - PubMed
  200. Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt A):2802-2810 - PubMed
  201. Nanotechnol Rev. 2015 Apr;3(2):111-122 - PubMed
  202. Front Pharmacol. 2018 Jul 17;9:790 - PubMed
  203. Beilstein J Nanotechnol. 2019 Dec 30;10:2594-2608 - PubMed
  204. Small. 2019 Oct;15(40):e1902998 - PubMed
  205. Expert Opin Ther Pat. 2016 Sep;26(9):1095-104 - PubMed
  206. Trends Biotechnol. 2017 May;35(5):434-451 - PubMed
  207. FEBS Lett. 2003 Jun 19;545(2-3):144-50 - PubMed
  208. Adv Drug Deliv Rev. 2017 Jun 1;115:115-154 - PubMed
  209. Nanomedicine. 2020 Feb;24:102127 - PubMed
  210. Cancer Lett. 2018 Jan 28;413:102-109 - PubMed
  211. Nanoscale. 2019 Jan 3;11(2):383-406 - PubMed
  212. Biomaterials. 2013 Mar;34(10):2516-23 - PubMed
  213. Mol Ther Methods Clin Dev. 2018 Sep 22;12:1-18 - PubMed
  214. Colloids Surf B Biointerfaces. 2020 Apr;188:110778 - PubMed
  215. J Biomol Struct Dyn. 2020 Jan 27;:1-8 - PubMed
  216. Mol Cancer. 2017 Jul 28;16(1):134 - PubMed
  217. Am J Cancer Res. 2019 May 01;9(5):945-958 - PubMed
  218. Chem Commun (Camb). 2018 Mar 25;54(24):3014-3017 - PubMed
  219. Cancer Treat Rev. 2017 Apr;55:128-135 - PubMed
  220. Clin Cancer Res. 2011 Jun 1;17(11):3520-6 - PubMed
  221. Acta Biomater. 2018 Oct 1;79:294-305 - PubMed
  222. Methods Mol Biol. 2019;1895:1-9 - PubMed
  223. Biomaterials. 2016 Oct;103:137-149 - PubMed
  224. Gene. 2019 Nov 30;719:144071 - PubMed
  225. Nat Rev Clin Oncol. 2019 May;16(5):281-295 - PubMed
  226. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10952-7 - PubMed
  227. Nanoscale. 2015 May 21;7(19):9083-91 - PubMed
  228. J Control Release. 2017 Jan 10;245:52-61 - PubMed
  229. Top Curr Chem (Cham). 2020 Jan 10;378(1):13 - PubMed
  230. Nanoscale Res Lett. 2018 Aug 28;13(1):254 - PubMed
  231. Nat Med. 2019 Oct;25(10):1488-1499 - PubMed
  232. Int J Biol Macromol. 2020 Jan 15;143:118-125 - PubMed
  233. Medchemcomm. 2019 Aug 16;10(10):1692-1718 - PubMed
  234. Mol Ther Nucleic Acids. 2019 Dec 6;18:927-937 - PubMed
  235. Am J Clin Oncol. 2014 Jun;37(3):261-5 - PubMed
  236. J Nanobiotechnology. 2019 Sep 3;17(1):93 - PubMed
  237. PLoS One. 2012;7(4):e34833 - PubMed
  238. Nanomedicine. 2011 Aug;7(4):472-9 - PubMed
  239. Biochimie. 2019 May;160:61-75 - PubMed
  240. Tumour Biol. 2015 Jul;36(7):4871-81 - PubMed
  241. Chem Sci. 2018 May 18;9(23):5260-5269 - PubMed
  242. Mol Ther Nucleic Acids. 2015 Sep 15;4:e252 - PubMed

Publication Types

Grant support